Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Slower Deal-Making Year In Oncology Leaves Numerous Appealing Targets

Executive Summary

In terms of oncology alliances, 2009 is shaping up as slower than the previous three years, but the number of significantly priced deals has not decreased greatly
Advertisement

Related Content

With Geron Deal Done, AngioChem Turns To Its Own Pipeline
Rexahn Looks For Breakthrough Year With Three Clinical Candidates
Rexahn Looks For Breakthrough Year With Three Clinical Candidates
Gloucester's Istodax Gains FDA Approval Ahead Of New Regulatory Requirements
Post-Market Requirements Could Broaden Label For Allos' Newly Approved PTCL Drug Folotyn
Allos' Folotyn and Gloucster's Istodax: Exceptions That Prove The Rule?
Glioblastoma Start-Ups Get Specific

Topics

Advertisement
UsernamePublicRestriction

Register

PS051717

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel